Stock Taper
Lantheus Holdings develops and markets diagnostic and therapeutic medical products, including imaging agents, radiotherapeutics, and AI software, serving healthcare providers worldwide to diagnose and treat various diseases.

PYLARIFY is Lantheus's top-selling, blockbuster PET imaging agent for prostate cancer, exceeding $1 billion in 2024, and is the first radiodiagnostic of its kind targeting PSMA-positive lesions.
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Product | $376.69M | $389.42M ▲ | $369.85M ▼ | $376.93M ▲ |
![]() | Oncology | — | — | $240.92M | $240.37M ▼ |
![]() | PYLARIFY | $240.62M | $240.2M ▼ | $240.92M ▲ | $240.37M ▼ |
![]() | Radiopharmaceutical Oncology | $240.62M | $240.2M ▼ | — | — |
![]() | Total Precision Diagnostics | $129.69M | $143.25M ▲ | — | — |
![]() | Cardiology | — | — | $84.63M | $88.28M ▲ |
![]() | DEFINITY | $81.78M | $85.31M ▲ | $84.63M ▼ | $88.28M ▲ |
![]() | Techne Lite | $21.13M | $20.98M ▼ | — | — |
![]() | Strategic Partnerships And Other | $13.71M | $23.34M ▲ | $16.34M ▼ | $19.92M ▲ |
![]() | License and Royalty Revenues | $7.33M | $17.36M ▲ | $7.48M ▼ | $11.25M ▲ |
![]() | Other Precision Diagnostics | $6.34M | $5.94M ▼ | — | — |
| Map | REGION | Q1-2026 | Q2-2026 |
|---|---|---|---|
![]() | UNITED STATES | $354.43M | $368.29M ▲ |
![]() | NonUS | $22.91M | $19.89M ▼ |
Overall rating: B+
| PEER | PRICE | |
|---|---|---|
PRAX | $344.75 | COMPARE |
CRNX | $84.84 | COMPARE |
HNGE | $87.35 | COMPARE |
AMRX | $17.54 | COMPARE |
ACAD | $29.11 | COMPARE |
INDV | $34.87 | COMPARE |
SUPN | $43.73 | COMPARE |
BHC | $6.32 | COMPARE |